Literature DB >> 3766258

Rat cytosolic epoxide hydrolase.

F Oesch, L Schladt, R Hartmann, C Timms, W Wörner.   

Abstract

Rat liver microsomal and cytosolic epoxide hydrolase may be distinguished through differences in substrate specificity: styrene 7,8-oxide is preferentially hydrolyzed by the microsomal form, while trans-stilbene oxide is the preferred substrate for cytosolic epoxide hydrolase. Large interindividual differences in the specific activity of Sprague-Dawley (outbred strain) liver cytosolic epoxide hydrolase were observed, varying from 2 to 77 pmol/min X mg protein. Interindividual variations were much lower for microsomal epoxide hydrolase. The specific activity of Fischer F-344 (inbred strain) liver cytosolic epoxide hydrolase varied only by a factor of 2. The specific activity of cytosolic epoxide hydrolase using trans-stilbene oxide as the substrate was highest in kidney and heart, followed by liver, brain, lung, testis, and spleen. For microsomal epoxide hydrolase, the specific activity was much lower in extrahepatic tissues than in liver. None of the commonly used inducers of xenobiotic metabolizing enzymes caused significant changes in rat liver cytosolic epoxide hydrolase. However, peroxisome proliferating drugs were found to drastically increase cytosolic epoxide hydrolase activity. Treatment for one week with a diet containing clofibrate (0.25%), tiadenol (0.5%) or acetylsalicylic acid (1%) caused a 8, 13 and 5 fold increase in cytosolic epoxide hydrolase activity respectively in the liver which parallelled the induction of peroxisomal beta-oxidation activity (13, 19 and 5 fold, respectively).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3766258     DOI: 10.1007/978-1-4684-5134-4_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

Review 1.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

2.  Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor: Crystallographic Snapshots of an Epoxide Hydrolase.

Authors:  Kelli L Hvorecny; Christopher D Bahl; Seiya Kitamura; Kin Sing Stephen Lee; Bruce D Hammock; Christophe Morisseau; Dean R Madden
Journal:  Structure       Date:  2017-04-06       Impact factor: 5.006

3.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2.

Authors:  Hiromasa Tanaka; Shizuo G Kamita; Nicola M Wolf; Todd R Harris; Zhaoju Wu; Christophe Morisseau; Bruce D Hammock
Journal:  Biochim Biophys Acta       Date:  2007-12-03

4.  Distribution and expression of soluble epoxide hydrolase in human brain.

Authors:  Priyanka Sura; Radhakrishna Sura; Ahmed E Enayetallah; David F Grant
Journal:  J Histochem Cytochem       Date:  2008-03-03       Impact factor: 2.479

Review 5.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.